

Freedom of Information Request: Our Reference CTMUHB_215_22

You asked:

Could you please tell me how many patients have been treated in the past 4 months with the following drugs:

- Erenumab (Aimovig) – for any disease
- Fremanezumab (Ajovy) – for any disease
- Galcanezumab (Emgality) – for any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – for migraine ONLY

Our response:

Please find below, tables populated with the data captured on our Medicine Management system for the period February 2022 to May 2022.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of Patients
Erenumab (Aimovig) – for any disease	6
Fremanezumab (Ajovy) – for any disease	23
Galcanezumab (Emgality) – for any disease	**
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – Please note our Medicine Management system does not capture patient details such as condition treated. Therefore, the number provided is for any disease and not migraine only.	16